MRTTSE:6034 63 EBITDA Margin % is -5.39% as of Mar. 2026. GuruFocus rates TSE:6034 with a GF Score™ of 63/100 and a GF Value™ of 円635.93 (Fairly Valued). The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, MRT ranks better than 50% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MRT's EBITDA for the
three
months ended in Mar. 2026 was 円-49 Mil. MRT's Revenue for the
three
months ended in Mar. 2026 was 円907 Mil. Therefore, MRT's EBITDA margin for the quarter that ended in Mar. 2026 was -5.39%.
MRT (TSE:6034) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MRT EBITDA Margin % Related Terms
MRT EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MRT's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6034 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, MRT's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MRT's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRT (TSE:6034) has a EBITDA Margin % of -5.39% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MRT and its competitors. According to the industry distribution chart, MRT ranks #333 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 50%.
Is MRT's EBITDA Margin % too high?
MRT's current EBITDA Margin % is -5.39%. Based on the distribution chart, MRT ranks #333 out of 666 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MRT has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MRT ranks #333 out of 666 companies for EBITDA Margin %. This puts MRT in the upper half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MRT and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MRT's current EBITDA Margin % is -5.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円635.93, compared to a current price of 円630.00 — trading 0.9% below its estimated fair value. The current EBITDA Margin % is -5.39%. MRT's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MRT (TSE:6034), the current EBITDA Margin % is -5.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be undervalued.
The current stock price of 円630.00 is trading 0.9% below its estimated GF Value™ of 円635.93.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
EBITDA Margin %: -5.39%
GF Value™: 円635.93 vs. price of 円630.00 (0.9% below fair value)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
63GF Score
Get the complete analysis for TSE:6034
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
